Kazia Therapeutics Joins Australian Consortium to Develop AI-Driven, Personalized Therapy Strategies for Childhood Brain Cancers

Reuters

2025/10/01

<a href="https://laohu8.com/S/KZA.AU">Kazia Therapeutics</a> Joins Australian Consortium to Develop AI-Driven, Personalized Therapy Strategies for Childhood Brain Cancers

Kazia Therapeutics Limited has announced its participation in a new Australian Medical Research Future Fund (MRFF) project aimed at improving treatment strategies for diffuse midline glioma (DMG), including diffuse intrinsic pontine glioma (DIPG). The three-year initiative, led by Professor Matt Dun of the University of Newcastle, will establish DMG-ADAPTS, an advanced AI-enabled clinical decision-making platform designed to optimize sequencing and timing of targeted therapies. Kazia will support the project by providing its investigational brain cancer drug paxalisib. The consortium will integrate multiomics data and non-invasive biomarkers to guide individualized therapy and anticipate resistance, with the goal of improving outcomes for children facing these aggressive brain tumors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kazia Therapeutics Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: CN88277) on October 01, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2572344875"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2572344875\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2572344875?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-01 21:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572344875","market":"fut","top_or_hot":-1,"title":"Kazia Therapeutics Joins Australian Consortium to Develop AI-Driven, Personalized Therapy Strategies for Childhood Brain Cancers","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KZA.AU\">Kazia Therapeutics</a> Joins Australian Consortium to Develop AI-Driven, Personalized Therapy Strategies for Childhood Brain Cancers\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/KZIA\">Kazia Therapeutics Limited</a> has announced its participation in a new Australian Medical Research Future Fund (MRFF) project aimed at improving treatment strategies for diffuse midline glioma (DMG), including diffuse intrinsic pontine glioma (DIPG). The three-year initiative, led by Professor Matt Dun of the University of Newcastle, will establish DMG-ADAPTS, an advanced AI-enabled clinical decision-making platform designed to optimize sequencing and timing of targeted therapies. Kazia will support the project by providing its investigational brain cancer drug paxalisib. The consortium will integrate multiomics data and non-invasive biomarkers to guide individualized therapy and anticipate resistance, with the goal of improving outcomes for children facing these aggressive brain tumors.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/NVGNF\">Kazia Therapeutics Limited</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN88277) on October 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kazia Therapeutics Joins Australian Consortium to Develop AI-Driven, Personalized Therapy Strategies for Childhood Brain Cancers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKazia Therapeutics Joins Australian Consortium to Develop AI-Driven, Personalized Therapy Strategies for Childhood Brain Cancers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-01 21:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/KZA.AU\">Kazia Therapeutics</a> Joins Australian Consortium to Develop AI-Driven, Personalized Therapy Strategies for Childhood Brain Cancers\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/KZIA\">Kazia Therapeutics Limited</a> has announced its participation in a new Australian Medical Research Future Fund (MRFF) project aimed at improving treatment strategies for diffuse midline glioma (DMG), including diffuse intrinsic pontine glioma (DIPG). The three-year initiative, led by Professor Matt Dun of the University of Newcastle, will establish DMG-ADAPTS, an advanced AI-enabled clinical decision-making platform designed to optimize sequencing and timing of targeted therapies. Kazia will support the project by providing its investigational brain cancer drug paxalisib. The consortium will integrate multiomics data and non-invasive biomarkers to guide individualized therapy and anticipate resistance, with the goal of improving outcomes for children facing these aggressive brain tumors.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/NVGNF\">Kazia Therapeutics Limited</a> published the original content used to generate this news brief via PR Newswire (Ref. ID: CN88277) on October 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KZIA","symbol_name":"Kazia Therapeutics Limited","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nNDL7KYCvR:1","article_id":"2572344875","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572344875","pubTimestamp":1759324911,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kazia Therapeutics Joins Australian Consortium to Develop AI-Driven, Personalized Therapy Strategies for Childhood Brain Cancers. Kazia Therapeutics Limited has announced its participation in a new Australian Medical Research Future Fund  project aimed at improving treatment strategies for diffuse midline glioma , including diffuse intrinsic pontine glioma . The three-year initiative, led by Professor Matt Dun of the University of Newcastle, will establish DMG-ADAPTS, an advanced AI-enabled clinical decision-making platform designed to optimize sequencing and timing of targeted therapies. Kazia will support the project by providing its investigational brain cancer drug paxalisib. The consortium will integrate multiomics data and non-invasive biomarkers to guide individualized therapy and anticipate resistance, with the goal of improving outcomes for children facing these aggressive brain tumors.Disclaimer: This news brief was created by Public Technologies  using generative artificial ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KZIA":"Kazia Therapeutics Limited","BK4139":"生物科技"},"translate_title":"Kazia Therapeutics加入澳大利亚财团，为儿童脑癌开发人工智能驱动的个性化治疗策略","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KZIA":0.9},"content_text":"Kazia Therapeutics Joins Australian Consortium to Develop AI-Driven, Personalized Therapy Strategies for Childhood Brain Cancers\n    \n\nKazia Therapeutics Limited has announced its participation in a new Australian Medical Research Future Fund (MRFF) project aimed at improving treatment strategies for diffuse midline glioma (DMG), including diffuse intrinsic pontine glioma (DIPG). The three-year initiative, led by Professor Matt Dun of the University of Newcastle, will establish DMG-ADAPTS, an advanced AI-enabled clinical decision-making platform designed to optimize sequencing and timing of targeted therapies. Kazia will support the project by providing its investigational brain cancer drug paxalisib. The consortium will integrate multiomics data and non-invasive biomarkers to guide individualized therapy and anticipate resistance, with the goal of improving outcomes for children facing these aggressive brain tumors.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kazia Therapeutics Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: CN88277) on October 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}